PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsErgotamine tartrate
Ergotamine tartrate
Caffeine / Ergotamine, Ergomar, Migergot (ergotamine tartrate) is a small molecule pharmaceutical. Ergotamine tartrate was first approved as Cafergot on 1982-01-01. It is used to treat cluster headache, migraine disorders, and postpartum hemorrhage in the USA.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ergomar
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
ergomarANDA2025-02-25
ergotamineANDA2013-04-10
ergotamine tartrate and caffeineANDA2025-03-27
migergotANDA2022-11-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
migraine disordersEFO_0003821D008881G43
cluster headache—D003027G44.00
postpartum hemorrhage—D006473O72
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02C: Antimigraine preparations
— N02CA: Ergot alkaloids, antimigraine
— N02CA02: Ergotamine
— N02CA52: Ergotamine, combinations excl. psycholeptics
— N02CA72: Ergotamine, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———31———3
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameErgotamine tartrate
INNergotamine
Description
Ergotamine is a peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. It has a role as a non-narcotic analgesic, a vasoconstrictor agent, a serotonergic agonist, an alpha-adrenergic agonist, a mycotoxin and an oxytocic. It is a conjugate base of an ergotamine(1+).
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Identifiers
PDB—
CAS-ID113-15-5
RxCUI4025
ChEMBL IDCHEMBL2448612
ChEBI ID—
PubChem CID8223
DrugBankDB00696
UNII IDPR834Q503T (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Migergot – Horizon Therapeutics Public
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,072 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ergomar, Ergotamine, Ergotamine tartrate and caffeine, Migergot
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
354 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use